C. O'Callaghan

474 total citations
14 papers, 360 citations indexed

About

C. O'Callaghan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Geriatrics and Gerontology. According to data from OpenAlex, C. O'Callaghan has authored 14 papers receiving a total of 360 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 3 papers in Geriatrics and Gerontology. Recurrent topics in C. O'Callaghan's work include Sirtuins and Resveratrol in Medicine (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Pancreatic and Hepatic Oncology Research (2 papers). C. O'Callaghan is often cited by papers focused on Sirtuins and Resveratrol in Medicine (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Pancreatic and Hepatic Oncology Research (2 papers). C. O'Callaghan collaborates with scholars based in United States, Canada and Ireland. C. O'Callaghan's co-authors include Athanassios Vassilopoulos, Órla P. Barry, Liam J. Fanning, Haiyan Jiang, Daniel R. Principe, Seong‐Hoon Park, Kirtee Raparia, Aileen Houston, Ha Yong Song and Yufan Yan and has published in prestigious journals such as Annals of Oncology, Science Translational Medicine and Oncotarget.

In The Last Decade

C. O'Callaghan

12 papers receiving 351 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. O'Callaghan United States 10 143 107 104 74 59 14 360
Erika Fiorino Italy 9 137 1.0× 37 0.3× 78 0.8× 70 0.9× 27 0.5× 15 330
Yosi Gozlan Israel 7 110 0.8× 181 1.7× 88 0.8× 72 1.0× 19 0.3× 11 356
Liyuan Liu China 9 88 0.6× 34 0.3× 31 0.3× 38 0.5× 29 0.5× 21 244
Daniela Diamanti Italy 8 133 0.9× 32 0.3× 36 0.3× 19 0.3× 23 0.4× 21 213
Chiara Spinelli Italy 12 99 0.7× 21 0.2× 22 0.2× 21 0.3× 37 0.6× 19 294
Shuying Zhu China 11 146 1.0× 21 0.2× 31 0.3× 21 0.3× 67 1.1× 34 305
Scott Boiko United States 5 116 0.8× 157 1.5× 37 0.4× 75 1.0× 10 0.2× 13 289
Jinghui Liang China 8 172 1.2× 9 0.1× 63 0.6× 14 0.2× 90 1.5× 23 350
Todd A. Fredrickson United States 11 360 2.5× 15 0.1× 79 0.8× 11 0.1× 12 0.2× 15 485
Theresa Swift‐Scanlan United States 14 493 3.4× 37 0.3× 112 1.1× 50 0.7× 156 2.6× 32 693

Countries citing papers authored by C. O'Callaghan

Since Specialization
Citations

This map shows the geographic impact of C. O'Callaghan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. O'Callaghan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. O'Callaghan more than expected).

Fields of papers citing papers by C. O'Callaghan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. O'Callaghan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. O'Callaghan. The network helps show where C. O'Callaghan may publish in the future.

Co-authorship network of co-authors of C. O'Callaghan

This figure shows the co-authorship network connecting the top 25 collaborators of C. O'Callaghan. A scholar is included among the top collaborators of C. O'Callaghan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. O'Callaghan. C. O'Callaghan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
Brown, Carl J., C. O'Callaghan, Jonathan M. Loree, et al.. (2024). 565P Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: The phase II NEO trial (CCTG CO.28) results after minimum 3 years follow up. Annals of Oncology. 35. S462–S463.
3.
Goss, Geraldine, Gail Darling, Virginie Westeel, et al.. (2024). LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC). Annals of Oncology. 35. S1238–S1238. 17 indexed citations
4.
Bregni, Giacomo, Nobuyuki Takemura, Yujiro Nishioka, et al.. (2024). 5MO Individual patient data (IPD) meta-analysis of randomised phase III trials (RP3) of chemotherapy for resectable colorectal cancer liver metastases (CRCLM): EORTC RP-2145. Annals of Oncology. 35. S4–S4. 2 indexed citations
5.
Chen, Chun-Hau, Ruchi Saxena, M. Naughton, et al.. (2021). ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. Science Translational Medicine. 13(577). 35 indexed citations
6.
7.
Ahmed, Mohamed A., et al.. (2020). Context-Dependent Roles for SIRT2 and SIRT3 in Tumor Development Upon Calorie Restriction or High Fat Diet. Frontiers in Oncology. 9. 1462–1462. 17 indexed citations
8.
O'Callaghan, C. & Athanassios Vassilopoulos. (2017). Sirtuins at the crossroads of stemness, aging, and cancer. Aging Cell. 16(6). 1208–1218. 148 indexed citations
9.
Song, Ha Yong, Marco Biancucci, C. O'Callaghan, et al.. (2016). SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status. Oncotarget. 7(49). 80336–80349. 32 indexed citations
10.
O'Callaghan, C., Liam J. Fanning, & Órla P. Barry. (2014). p38δ MAPK phenotype. Anti-Cancer Drugs. 26(1). 46–55. 10 indexed citations
11.
O'Callaghan, C., Liam J. Fanning, & Órla P. Barry. (2014). p38δMAPK: Emerging Roles of a Neglected Isoform. International Journal of Cell Biology. 2014. 1–12. 23 indexed citations
12.
O'Callaghan, C., Liam J. Fanning, Aileen Houston, & Órla P. Barry. (2013). Loss of p38δ mitogen-activated protein kinase expression promotes oesophageal squamous cell carcinoma proliferation, migration and anchorage-independent growth. International Journal of Oncology. 43(2). 405–415. 13 indexed citations
13.
O'Callaghan, C., Kun Ding, D.P. Dearnaley, et al.. (2011). 517 oral QOL / OUTCOMES OF AN INTERNATIONAL PHASE 3 TRIAL OF INTERMITTENT V CONTINUOUS HORMONE THERAPY FOR RELAPSED PROSTATE CA. Radiotherapy and Oncology. 99. S210–S210. 3 indexed citations
14.
O'Callaghan, C.. (2009). Objectivist and Constructivist Music Therapy Research in Oncology and Palliative Care: An Overview and Reflection. Music and Medicine. 1(1). 41–60. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erika Fiorino Breakdown of academic impact, for papers by Yosi Gozlan Breakdown of academic impact, for papers by Liyuan Liu Breakdown of academic impact, for papers by Daniela Diamanti Breakdown of academic impact, for papers by Chiara Spinelli Breakdown of academic impact, for papers by Shuying Zhu Breakdown of academic impact, for papers by Scott Boiko Breakdown of academic impact, for papers by Jinghui Liang Breakdown of academic impact, for papers by Todd A. Fredrickson Breakdown of academic impact, for papers by Theresa Swift‐Scanlan
Rankless by CCL
2026